Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert W Leong

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Journal of Gastroenterology and Hepatology|November 4, 2021
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseasesKaren M J Waller, Rupert W Leong, Sudarshan Paramsothy
The American Journal of Gastroenterology|October 25, 2021
Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-AnalysisRobyn Laube, Yvonne Tran, Sudarshan Paramsothy, et al.
World Journal of Clinical Cases|April 18, 2022
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literatureMichael Au, Nikola Mitrev, Rupert W Leong, et al.
Journal of Clinical Gastroenterology|December 2, 2024
Comment on: Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-severe Ulcerative Colitis: A Prospective Multicenter Cohort (MOSAIK) StudyFadi H Mourad, Viraj C Kariyawasam, Rupert W Leong
Alimentary Pharmacology & Therapeutics|June 21, 2021
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyYanna Ko, Sudarshan Paramsothy, Yunki Yau, et al.
Therapeutic Advances in Gastroenterology|March 14, 2022
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyAviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy, et al.
Gastrointestinal Endoscopy Clinics of North America|July 1, 2014
Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitisRupert W Leong, Rhys O Butcher, Michael F Picco
World Journal of Gastrointestinal Pathophysiology|February 25, 2016
Current application of proteomics in biomarker discovery for inflammatory bowel diseasePatrick Py Chan, Valerie C Wasinger, Rupert W Leong
Internal Medicine Journal|November 20, 2020
Tioguanine as an alternative immunomodulator in inflammatory bowel diseasesMohammad Shir Ali, Robyn Laube, Sriharan Selvaratnam, et al.
Journal of Gastroenterology and Hepatology|March 16, 2013
Proteomics and metabolomics in inflammatory bowel diseaseYunki Yau, Rupert W Leong, Ming Zeng, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Journal of Gastroenterology and Hepatology|November 4, 2021
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseasesKaren M J Waller, Rupert W Leong, Sudarshan Paramsothy
The American Journal of Gastroenterology|October 25, 2021
Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-AnalysisRobyn Laube, Yvonne Tran, Sudarshan Paramsothy, et al.
World Journal of Clinical Cases|April 18, 2022
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literatureMichael Au, Nikola Mitrev, Rupert W Leong, et al.
Journal of Clinical Gastroenterology|December 2, 2024
Comment on: Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-severe Ulcerative Colitis: A Prospective Multicenter Cohort (MOSAIK) StudyFadi H Mourad, Viraj C Kariyawasam, Rupert W Leong
Alimentary Pharmacology & Therapeutics|June 21, 2021
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyYanna Ko, Sudarshan Paramsothy, Yunki Yau, et al.
Therapeutic Advances in Gastroenterology|March 14, 2022
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyAviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy, et al.
Gastrointestinal Endoscopy Clinics of North America|July 1, 2014
Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitisRupert W Leong, Rhys O Butcher, Michael F Picco
World Journal of Gastrointestinal Pathophysiology|February 25, 2016
Current application of proteomics in biomarker discovery for inflammatory bowel diseasePatrick Py Chan, Valerie C Wasinger, Rupert W Leong
Internal Medicine Journal|November 20, 2020
Tioguanine as an alternative immunomodulator in inflammatory bowel diseasesMohammad Shir Ali, Robyn Laube, Sriharan Selvaratnam, et al.
Journal of Gastroenterology and Hepatology|March 16, 2013
Proteomics and metabolomics in inflammatory bowel diseaseYunki Yau, Rupert W Leong, Ming Zeng, et al.
Pageof 16